AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir...
(Source: AbbVie Inc) Mar 30, 2016 NORTH CHICAGO, Ill., March 30, 2016 /PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained...
View ArticleAbbVie Announces Real-World Data with VIEKIRAX®...
BARCELONA, Spain, April 15, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505...
View ArticleEnanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s...
(Source: Enanta Pharmaceuticals Inc) AbbVie reports 98 percent of previously untreatedgenotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVRin Phase 3b...
View ArticleEnanta Pharmaceuticals Announces Preliminary Data from AbbVie’s Phase 3b...
(Source: Enanta Pharmaceuticals Inc) Enanta Pharmaceuticals Announces Preliminary Data from AbbVie's Phase 3b RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment Presented at The...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
- 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1) NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ --...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
(Source: AbbVie Inc) - 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1) NORTH CHICAGO, Ill. , June 24,...
View ArticleAbbVie to Present New Data from Hepatitis C Clinical Development Program at...
NORTH CHICAGO, Ill., April 8, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that 29 abstracts from its ongoing hepatitis C clinical development program have been accepted for presentation...
View ArticleAbbVie to Present New Data from Hepatitis C Clinical Development Program at...
- 29 abstracts, including sub-analyses of AbbVie's approved treatment of VIEKIRAX® + EXVIERA®, as well as new data from Phase 3b development program and AbbVie's HCV pipeline compounds NORTH CHICAGO,...
View ArticleAbbVie to Present New Data from Hepatitis C Clinical Development Program at...
(Source: AbbVie Inc) - 29 abstracts, including sub-analyses of AbbVie's approved treatment of VIEKIRAX® + EXVIERA®, as well as new data from Phase 3b development program and AbbVie's HCV pipeline...
View ArticleEnanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless...
(Source: Enanta Pharmaceuticals Inc) 100 percent of genotype 1b (GT1b) patients who received VIEKIRAX + EXVIERA without ribavirin for 12 weeks, achieved SVRin a post-hoc analysis,regardless of whether...
View ArticleAbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® +...
VIENNA, April 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study. RUBY-I is evaluating...
View ArticleAbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® +...
- RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment - In preliminary data from RUBY-I, patients receiving VIEKIRAX + EXVIERA with or...
View ArticleAbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® +...
(Source: AbbVie Inc) - RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment - In preliminary data from RUBY-I, patients receiving...
View ArticleAbbVie Announces High SVR Rates with VIEKIRAX®...
BARCELONA, Spain, April 14, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus...
View ArticleViiV Healthcare announces phase II study results for first two drug,...
(Source: GSK - GlaxoSmithKline plc) 32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen Issued: London London,...
View ArticleFirst Regimen Combining Long Acting Injectable Antiretrovirals; 32-Week LATTE...
(Source: Johnson & Johnson) Intramuscular 2-drug maintenance therapy demonstrates comparable antiviral activity to daily oral 3-drug combination CORK, Ireland, - February 24, 2016 - Janssen...
View ArticleViiV Healthcare begins phase III programme with dolutegravir/rilpivirine...
(Source: GSK - GlaxoSmithKline plc) 06 May 2015 First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine London, United Kingdom, 6 May 2015: ViiV Healthcare today...
View ArticleViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine...
First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine LONDON, May 6, 2015 /CNW/ - ViiV Healthcare today announced the start of a Phase III clinical trial programme...
View ArticleJanssen to Progress Collaboration with ViiV Healthcare to Develop the First...
(Source: Johnson & Johnson) 5bdf0770-87c8-4b68-992a-859cfe2ae0b0.pdf January 7, 2016 Janssen to Progress Collaboration with ViiV Healthcare to Develop the First Long Acting Two Drug Injectable...
View Article